Kidney Transplant Clinical Trial
Official title:
KidneyCare Immuno-optimization in Renal Allografts
Verified date | March 2023 |
Source | CareDx |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an unblinded, randomized, four-arm interventional research study enrolling patients who are undergoing kidney transplantation. The aim of the study is to determine whether patients at low risk of rejection can safely reduce the doses of their post-transplant immunosuppression medications using a combination of tests that include donor-specific antibodies (DSA), histology (looking at tissue from the donor graft), and donor-derived cell-free DNA (AlloSure). Eligible participants will be randomized in a 2:1 ratio into one of two immune-optimization (intervention) arms or the corresponding observational (control) arms. Two thirds of the participants in the study will have their decision to reduce immunosuppression made based on these test results and the other third will have the decision made based on standard of care clinical assessment and laboratory testing. The study will include two additional parameters under investigation - the AlloMap Kidney gene expression profiling test and the iBox prediction algorithm, but these will not be actively used to make any decisions as part of the trial. AlloSure, AlloMap Kidney, and iBox are the three components of the KidneyCare panel developed by CareDx.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 23, 2023 |
Est. primary completion date | February 23, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Participant is willing and able to give informed consent for participation in the trial 2. Patients aged 18 years or older 3. cPRA <20% & no preformed DSA at time of transplant (using center-specific threshold) 4. Recipient (or planned recipient, if pre-transplant) of single, first-time, deceased (DBD/DCD) or living donor Kidney Transplant 5. Planned post-transplant maintenance immunosuppression regimen consisting of tacrolimus and MMF, with or without prednisone 6. Negative virtual crossmatch (performed by transplant center) 7. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception during the trial 8. In the Investigator's opinion, is able and willing to comply with all trial requirements Exclusion Criteria: The participant may not enter the trial if ANY of the following apply: 1. Female participant who is pregnant, lactating, or planning pregnancy during the trial 2. Preformed DSA or ABO incompatible transplant 3. Chronic oral steroid use (for any reason) 4. Planned post-transplant immunosuppression regimen utilizing cyclosporine, azathioprine, mTOR inhibitors, and/or co-stimulatory blockers 5. Donor organ from identical twin or history of prior kidney transplant 6. Multivisceral transplant (heart/kidney, kidney/pancreas, liver/kidney, etc.) or history of hematopoietic stem cell transplant 7. Participant with life expectancy of less than 6 months or is inappropriate for immuno-optimization (including those patients at increased risk of primary disease recurrence w/ reduction in post-transplant immunosuppression) 8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial 9. Participants who are currently or have previously participated in another research trial involving an investigational drug/product in the past 12 weeks 10. Any condition that would preclude protocol biopsies (e.g. patients on lifelong anticoagulation for whom anticoagulation cannot be safely held) Randomization Criteria (assessed at 3 months) The participant may not proceed with randomization if ANY of the following apply: 1. Maintenance immunosuppression that includes cyclosporine, azathioprine, mTOR inhibitors, and/or co-stimulatory blockers 2. Baseline proteinuria =0.5g/day (confirmed by repeat measurement) 3. Baseline eGFR <45mL/min (average of 3 most recent prior readings) 4. Any episodes of biopsy-proven acute rejection (TCMR =1A or ABMR) since the time of transplant 5. Any interval detection of de novo DSA since the time of transplant (per center-specific threshold) 6. AlloSure result >0.5% at Month 3 |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CareDx |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of clinically-relevant infections among study participants (defined as infection requiring inpatient admission for evaluation/treatment) | Assessment of all medical events throughout the duration of the study. | 24 months | |
Other | Correlation between longitudinal AlloMap Kidney Scores / iBox Results and dosing of immunosuppressive agents | Assess utility of AlloMap Kidney and iBox results for purposes of immuno-optimization and post-transplant surveillance | 24 months | |
Other | Correlation between longitudinal AlloMap Kidney Scores / iBox Results and eFGR. | Assess utility of AlloMap Kidney and iBox results for purposes of immuno-optimization and post-transplant surveillance | 24 months | |
Other | Correlation between longitudinal AlloMap Kidney Scores / iBox Results and dnDSA rate. | Assess utility of AlloMap Kidney and iBox results for purposes of immuno-optimization and post-transplant surveillance | 24 months | |
Other | Correlation between cross-sectional AlloMap Kidney Scores / iBox Results and rejection (TCMR, ABMR) on histology from for-cause & surveillance biopsies. | Assess utility of AlloMap Kidney and iBox results for purposes of immuno-optimization and post-transplant surveillance | 24 months | |
Other | Correlation between cross-sectional AlloMap Kidney Scores / iBox Results and severity/grading of transplant glomerulopathy and IFTA on for-cause & surveillance biopsies | Assess utility of AlloMap Kidney and iBox results for purposes of immuno-optimization and post-transplant surveillance | 24 months | |
Other | Immunosuppression Dosing | Comparison of cumulative immunosuppression exposure in each arm (average daily dose over time) | 24 months | |
Other | Immunosuppression Exposure | Comparison of final dosage of each immunosuppressive agent at the conclusion of the study in each arm (tacrolimus, mycophenolate/Myfortic, prednisone) | 24 months | |
Other | Incidence of viremia ( including BK & CMV), defined as copies/mL in excess of the limit of detection | Assessment of all medical events throughout the duration of the study | 24 months | |
Other | PCR viral load over time (defined as time to resolution after initial identification of infection) | Assessment of all medical events throughout the duration of the study | 24 months | |
Other | Incidence of any associated end-organ manifestations of viral infection | Assessment of all medical events throughout the duration of the study | 24 months | |
Other | Changes in immunosuppression, defined as the change in the median daily dose (mg/day) of immunosuppressive agents | Assessment of all medical events throughout the duration of the study | 24 months | |
Other | Incidence of proteinuria, defined by urine protein to creatinine ratio >0.5g/g, confirmed on serial samples | Assessment of all medical events throughout the duration of the study | 24 months | |
Other | Number of clinically defined and/or biopsy-confirmed allograft rejection events, including the specific histologic diagnosis made, and if treated, description and duration of therapeutic regimen | Assessment of all medical events throughout the duration of the study | 24 months | |
Primary | Estimated glomerular filtration rate (eGFR) at 12 months, non-inferiority | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (safety endpoint) | 12 months | |
Primary | Estimated glomerular filtration rate (eGFR) at 24 months, non-inferiority | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (safety endpoint) | 24 months | |
Primary | Interstitial fibrosis/tubular atrophy (IF/TA) quantified by Banff Working Group biopsy grade(s) at 12-months post-transplant | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (safety) | 12 months | |
Primary | Interstitial fibrosis/tubular atrophy (IF/TA) quantified by Banff Working Group biopsy grade(s) at 24-months post-transplant | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (safety) | 24 months | |
Primary | Transplant glomerulopathy (TG) at 12-months post-transplant, quantified by biopsy-based histopathology grade(s) | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (safety) | 12 months | |
Primary | Transplant glomerulopathy (TG) at 24-months post-transplant, quantified by biopsy-based histopathology grade(s) | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (safety) | 24 months | |
Primary | Total number of biopsies performed post-transplant, including both surveillance and clinically indicated biopsies | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (efficacy) | 24 months | |
Primary | Number of clinically indicated biopsies planned and performed in the first 12- months post- transplant | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (efficacy) | 12 months | |
Primary | Number of clinically indicated biopsies planned and performed in the 24-months post- transplant | Demonstrate the safety and efficacy of KidneyCare as tool to successfully adjust immunosuppressant agents using regular surveillance for safe drug minimization. (efficacy) | 24 months | |
Secondary | Histological assessment of tissue biopsy with paired AlloSure dd-cfDNA result - performed both 'For Cause' and 'Surveillance', using standard biopsy and HistoMap molecular assessment using nCounter. | Identify correlation between dd-cfDNA and histopathological allograft rejection based on all clinical biopsies. | 24 months | |
Secondary | Results of DSA testing, performed as outlined in the testing schedule | Compare rates of de-novo DSA antibody formation in immuno-optimization and control groups. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087720 -
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
|
Phase 4 | |
Completed |
NCT03749356 -
Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients
|
Phase 4 | |
Withdrawn |
NCT05811468 -
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
|
||
Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
Completed |
NCT00498576 -
Melatonin and Adiponectin in Hypertensive Kidney Transplant
|
N/A | |
Completed |
NCT00642655 -
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT00374400 -
The Paired Donation Consortium Paired Donation Program
|
N/A | |
Completed |
NCT01710033 -
A Study Of CP-690,550 In Stable Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT00205257 -
Prediction of Acute Rejection in Renal Transplant
|
Phase 1 | |
Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03978494 -
Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
|
Phase 1 | |
Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT03644485 -
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT02409901 -
Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01047410 -
ACtive Care After Transplantation, the ACT Study
|
N/A | |
Completed |
NCT00940940 -
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
|
Phase 4 | |
Completed |
NCT00217126 -
The Study of Long-term Deterioration of Kidney Transplants.
|
Phase 4 | |
Completed |
NCT00270712 -
A Study of Factors That Affect Long-Term Kidney Transplant Function
|